EXPERIENCE IN APPLICATION OF CANAKINUMAB IN PATIENTS WITH CRYOPYRIN-ASSOCIATED SYNDROME (SYNDROME CINCA/NOMID)
The article describes the monitoring of severe cryopyrin-associated syndrome (syndrome CINCA/NOMID). The following clinical case indicates successful application of homogeneous antibodies to interleukin 1 — canakinumab — in patient with chronic neurologic dermatic articular syndrome. Fever, rush and...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
"Paediatrician" Publishers LLC
2014-05-01
|
| Series: | Вопросы современной педиатрии |
| Subjects: | |
| Online Access: | https://vsp.spr-journal.ru/jour/article/view/199 |
| _version_ | 1797697638942900224 |
|---|---|
| author | T. V. Sleptsova E. I. Alexeeva K. V. Savost’yanov A. A. Pushkov A. G. Nikitin T. M. Bzarova S. I. Valieva A. N. Fetisova A. V. Pakhomov N. V. Zhurkova R. V. Denisova K. B. Isaeva E. G. Chistyakova |
| author_facet | T. V. Sleptsova E. I. Alexeeva K. V. Savost’yanov A. A. Pushkov A. G. Nikitin T. M. Bzarova S. I. Valieva A. N. Fetisova A. V. Pakhomov N. V. Zhurkova R. V. Denisova K. B. Isaeva E. G. Chistyakova |
| author_sort | T. V. Sleptsova |
| collection | DOAJ |
| description | The article describes the monitoring of severe cryopyrin-associated syndrome (syndrome CINCA/NOMID). The following clinical case indicates successful application of homogeneous antibodies to interleukin 1 — canakinumab — in patient with chronic neurologic dermatic articular syndrome. Fever, rush and pain syndrome completely jugulated, contractures of articulation joints decreased in a week since the beginning of the treatment. In 8 weeks of therapy movements of affected joints almost completely restored, the boy could stay, spell simple words; decreased and normalized laboratory test values of disease activity (erythrocyte sedimentation rate, C-reactive protein). In 12 weeks the child could move with assistance, say simple phrases. The following clinical case shows high efficiency of application of canakinumab in chronic neurologic dermatic articular syndrome treatment and indicates the perspectives of therapeutic use of interleukin 1 blocking agent in patients with early stage of disease before the progress of nonreversible osteohondrous destruction and serious injury of cerebrospinal nervous system. No adverse event were registered on treatment with application of canakinumab.Key words: children, autophologistic syndromes, cryopyrin-associated syndrome, CINCA/NOMID, canakinumab. |
| first_indexed | 2024-03-12T03:42:57Z |
| format | Article |
| id | doaj.art-c4e2f6cb60724f079bcaac6c72e71609 |
| institution | Directory Open Access Journal |
| issn | 1682-5527 1682-5535 |
| language | English |
| last_indexed | 2024-03-12T03:42:57Z |
| publishDate | 2014-05-01 |
| publisher | "Paediatrician" Publishers LLC |
| record_format | Article |
| series | Вопросы современной педиатрии |
| spelling | doaj.art-c4e2f6cb60724f079bcaac6c72e716092023-09-03T13:02:26Zeng"Paediatrician" Publishers LLCВопросы современной педиатрии1682-55271682-55352014-05-011339710310.15690/vsp.v13i3.1035199EXPERIENCE IN APPLICATION OF CANAKINUMAB IN PATIENTS WITH CRYOPYRIN-ASSOCIATED SYNDROME (SYNDROME CINCA/NOMID)T. V. Sleptsova0E. I. Alexeeva1K. V. Savost’yanov2A. A. Pushkov3A. G. Nikitin4T. M. Bzarova5S. I. Valieva6A. N. Fetisova7A. V. Pakhomov8N. V. Zhurkova9R. V. Denisova10K. B. Isaeva11E. G. Chistyakova12Научный центр здоровья детей, МоскваНаучный центр здоровья детей, Москва; Первый Московский государственный медицинский университет им. И.М. СеченоваНаучный центр здоровья детей, МоскваНаучный центр здоровья детей, МоскваНаучный центр здоровья детей, МоскваНаучный центр здоровья детей, МоскваНаучный центр здоровья детей, МоскваНаучный центр здоровья детей, МоскваНаучный центр здоровья детей, МоскваНаучный центр здоровья детей, МоскваНаучный центр здоровья детей, МоскваНаучный центр здоровья детей, МоскваНаучный центр здоровья детей, Москва; Первый Московский государственный медицинский университет им. И.М. СеченоваThe article describes the monitoring of severe cryopyrin-associated syndrome (syndrome CINCA/NOMID). The following clinical case indicates successful application of homogeneous antibodies to interleukin 1 — canakinumab — in patient with chronic neurologic dermatic articular syndrome. Fever, rush and pain syndrome completely jugulated, contractures of articulation joints decreased in a week since the beginning of the treatment. In 8 weeks of therapy movements of affected joints almost completely restored, the boy could stay, spell simple words; decreased and normalized laboratory test values of disease activity (erythrocyte sedimentation rate, C-reactive protein). In 12 weeks the child could move with assistance, say simple phrases. The following clinical case shows high efficiency of application of canakinumab in chronic neurologic dermatic articular syndrome treatment and indicates the perspectives of therapeutic use of interleukin 1 blocking agent in patients with early stage of disease before the progress of nonreversible osteohondrous destruction and serious injury of cerebrospinal nervous system. No adverse event were registered on treatment with application of canakinumab.Key words: children, autophologistic syndromes, cryopyrin-associated syndrome, CINCA/NOMID, canakinumab.https://vsp.spr-journal.ru/jour/article/view/199детиаутовоспалительные синдромыкриопиринассоциированный синдромcinca/nomidканакинумаб |
| spellingShingle | T. V. Sleptsova E. I. Alexeeva K. V. Savost’yanov A. A. Pushkov A. G. Nikitin T. M. Bzarova S. I. Valieva A. N. Fetisova A. V. Pakhomov N. V. Zhurkova R. V. Denisova K. B. Isaeva E. G. Chistyakova EXPERIENCE IN APPLICATION OF CANAKINUMAB IN PATIENTS WITH CRYOPYRIN-ASSOCIATED SYNDROME (SYNDROME CINCA/NOMID) Вопросы современной педиатрии дети аутовоспалительные синдромы криопиринассоциированный синдром cinca/nomid канакинумаб |
| title | EXPERIENCE IN APPLICATION OF CANAKINUMAB IN PATIENTS WITH CRYOPYRIN-ASSOCIATED SYNDROME (SYNDROME CINCA/NOMID) |
| title_full | EXPERIENCE IN APPLICATION OF CANAKINUMAB IN PATIENTS WITH CRYOPYRIN-ASSOCIATED SYNDROME (SYNDROME CINCA/NOMID) |
| title_fullStr | EXPERIENCE IN APPLICATION OF CANAKINUMAB IN PATIENTS WITH CRYOPYRIN-ASSOCIATED SYNDROME (SYNDROME CINCA/NOMID) |
| title_full_unstemmed | EXPERIENCE IN APPLICATION OF CANAKINUMAB IN PATIENTS WITH CRYOPYRIN-ASSOCIATED SYNDROME (SYNDROME CINCA/NOMID) |
| title_short | EXPERIENCE IN APPLICATION OF CANAKINUMAB IN PATIENTS WITH CRYOPYRIN-ASSOCIATED SYNDROME (SYNDROME CINCA/NOMID) |
| title_sort | experience in application of canakinumab in patients with cryopyrin associated syndrome syndrome cinca nomid |
| topic | дети аутовоспалительные синдромы криопиринассоциированный синдром cinca/nomid канакинумаб |
| url | https://vsp.spr-journal.ru/jour/article/view/199 |
| work_keys_str_mv | AT tvsleptsova experienceinapplicationofcanakinumabinpatientswithcryopyrinassociatedsyndromesyndromecincanomid AT eialexeeva experienceinapplicationofcanakinumabinpatientswithcryopyrinassociatedsyndromesyndromecincanomid AT kvsavostyanov experienceinapplicationofcanakinumabinpatientswithcryopyrinassociatedsyndromesyndromecincanomid AT aapushkov experienceinapplicationofcanakinumabinpatientswithcryopyrinassociatedsyndromesyndromecincanomid AT agnikitin experienceinapplicationofcanakinumabinpatientswithcryopyrinassociatedsyndromesyndromecincanomid AT tmbzarova experienceinapplicationofcanakinumabinpatientswithcryopyrinassociatedsyndromesyndromecincanomid AT sivalieva experienceinapplicationofcanakinumabinpatientswithcryopyrinassociatedsyndromesyndromecincanomid AT anfetisova experienceinapplicationofcanakinumabinpatientswithcryopyrinassociatedsyndromesyndromecincanomid AT avpakhomov experienceinapplicationofcanakinumabinpatientswithcryopyrinassociatedsyndromesyndromecincanomid AT nvzhurkova experienceinapplicationofcanakinumabinpatientswithcryopyrinassociatedsyndromesyndromecincanomid AT rvdenisova experienceinapplicationofcanakinumabinpatientswithcryopyrinassociatedsyndromesyndromecincanomid AT kbisaeva experienceinapplicationofcanakinumabinpatientswithcryopyrinassociatedsyndromesyndromecincanomid AT egchistyakova experienceinapplicationofcanakinumabinpatientswithcryopyrinassociatedsyndromesyndromecincanomid |